Evinacumab
Evkeeza (evinacumab) is an antibody pharmaceutical. Evinacumab was first approved as Evkeeza on 2021-02-11. It has been approved in Europe to treat hypercholesterolemia. The pharmaceutical is active against angiopoietin-related protein 3.
| Trade Name | Evkeeza |
|---|---|
| Common Name | Evinacumab |
| Indication | hypercholesterolemia |
| Drug Class | Monoclonal antibodies: fully human, cardiovascular indications; vinca alkaloids |
